BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment - 2Must-See Public Parks from Around the Globe
- 3Vote in favor of your Favored kind of pasta
- 4Figurine of a woman and a goose offers peek at prehistoric beliefs
- 5Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Vote In favor of Your Favored Kind Of Organic product
- Favored Vehicle for Seniors: Make Your Determination
- In vogue Sleepwear Patterns for 2024
- Party Urban areas of the World
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Asia's Noteworthy Destinations: A Voyager's Aide
- Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions
- Scientists find new clues to why female fertility declines with age
